COMPANY

Cenna Biosciences

HQ: La Jolla, CA source · cennabiosciences.com ↗ · West Coast

Clinical Phase 1

Location: La Jolla, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

Keywords: alzheimer's disease

1Trials (company is sponsor)14NIH grants

Timeline

Sep 15, 2026 Trial start 1: Phase 1 Study to Evaluate the Safety and Tolerability of 8M2D in Healthy People and Alzheimer's Patients source ↗
Aug 5, 2025 Grant Government grant — SBIR: $1.63M (annual award, as published), announced Aug 5, 2025. Agency: NIH/NIA. Source: government award database. source ↗

Upcoming milestones

2027-09 (ESTIMATED) · 1 · Phase 1 Study to Evaluate the Safety and Tolerability of 8M2D in Healthy People and Alzheimer's Patients · NCT07568041

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Aug 5, 2025 Government grant — SBIR: $1.63M (annual award, as published), announced Aug 5, 2025. Agency: NIH/NIA. Source: government award database. source ↗

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT07568041	Phase 1 Study to Evaluate the Safety and Tolerability of 8M2D in Healthy People and Alzheimer's Patients	1	Not yet recruiting	Sep 15, 2026	2027-09 (estimated)

NIH awards 14

Annual award amounts. Total $10.5M.

Sep 19, 2024 NIH award 1R44AG087853-01A1 FY2024: $1,041,646 awarded for that fiscal year; activity R44 (SBIR); PI DEWJI, NAZNEEN N; recipient as written: CENNA BIOSCIENCES, INC., LA JOLLA, CA. EARLY CLINICAL DEVELOPMENT OF MODIFI source ↗
Aug 17, 2021 NIH award 3R44AG043278-07S1 FY2021: $101,144 awarded for that fiscal year; activity R44 (SBIR); PI DEWJI, NAZNEEN N; recipient as written: CENNA BIOSCIENCES, INC., LA JOLLA, CA. IND-Enabling Pre-clinical Development source ↗
Jul 6, 2021 NIH award 5R44AG043278-07 FY2021: $1,610,358 awarded for that fiscal year; activity R44 (SBIR); PI DEWJI, NAZNEEN N; recipient as written: CENNA BIOSCIENCES, INC., LA JOLLA, CA. IND-Enabling Pre-clinical Development source ↗
Sep 11, 2020 NIH award 2R44AG043278-06A1 FY2020: $1,750,000 awarded for that fiscal year; activity R44 (SBIR); PI DEWJI, NAZNEEN N; recipient as written: CENNA BIOSCIENCES, INC., LA JOLLA, CA. IND-Enabling Pre-clinical Developmen source ↗
Aug 31, 2019 NIH award 3R44AG055182-03S1 FY2019: $374,500 awarded for that fiscal year; activity R44 (SBIR); PI DEWJI, NAZNEEN N; recipient as written: CENNA BIOSCIENCES, INC., LA JOLLA, CA. Small molecule therapeutics for Alzhei source ↗
Apr 19, 2019 NIH award 5R44AG055182-03 FY2019: $999,998 awarded for that fiscal year; activity R44 (SBIR); PI DEWJI, NAZNEEN N; recipient as written: CENNA BIOSCIENCES, INC., LA JOLLA, CA. Small molecule therapeutics for Alzheime source ↗
Sep 20, 2018 NIH award 2R44AG055182-02 FY2018: $999,998 awarded for that fiscal year; activity R44 (SBIR); PI DEWJI, NAZNEEN N; recipient as written: CENNA BIOSCIENCES, INC., LA JOLLA, CA. Small molecule therapeutics for Alzheime source ↗
Jun 25, 2018 NIH award 5R44AG043278-05 FY2018: $747,850 awarded for that fiscal year; activity R44 (SBIR); PI DEWJI, NAZNEEN N; recipient as written: CENNA BIOSCIENCES, INC., LA JOLLA, CA. Progressing the Pre-clinical development source ↗
Sep 8, 2017 NIH award 2R44AG043278-04 FY2017: $750,000 awarded for that fiscal year; activity R44 (SBIR); PI DEWJI, NAZNEEN N; recipient as written: CENNA BIOSCIENCES, INC., LA JOLLA, CA. Progressing the Pre-clinical development source ↗
Aug 31, 2017 NIH award 3R44AG043278-03S1 FY2017: $99,960 awarded for that fiscal year; activity R44 (SBIR); PI DEWJI, NAZNEEN N; recipient as written: CENNA BIOSCIENCES, INC., LA JOLLA, CA. Intranasal Delivery of Peptide Drugs to source ↗
Sep 21, 2016 NIH award 1R43AG055182-01 FY2016: $225,000 awarded for that fiscal year; activity R43 (SBIR); PI DEWJI, NAZNEEN N; recipient as written: CENNA BIOSCIENCES, INC., LA JOLLA, CA. Small molecule therapeutics for Alzheime source ↗
May 11, 2016 NIH award 5R44AG043278-03 FY2016: $746,899 awarded for that fiscal year; activity R44 (SBIR); PI DEWJI, NAZNEEN N; recipient as written: CENNA BIOSCIENCES, INC., LA JOLLA, CA. Intranasal Delivery of Peptide Drugs to source ↗
May 18, 2015 NIH award 2R44AG043278-02A1 FY2015: $750,000 awarded for that fiscal year; activity R44 (SBIR); PI DEWJI, NAZNEEN N; recipient as written: CENNA BIOSCIENCES, INC., LA JOLLA, CA. Intranasal Delivery of Peptide Drugs t source ↗
Jul 26, 2012 NIH award 1R43AG043278-01 FY2012: $261,779 awarded for that fiscal year; activity R43 (SBIR); PI DEWJI, NAZNEEN N; recipient as written: CENNA BIOSCIENCES, INC., LA JOLLA, CA. Intranasal Delivery of Peptide Drugs to source ↗